Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

BIO 2013 Monday Roundup: Bayer, Orphan Drug Pricing, Avalon/GSK

This article was originally published in The Pink Sheet Daily

Executive Summary

Our survey of news from the first day of BIO 2013 includes a look at Bayer’s business development plans, Avalon Ventures’ tie-up with GlaxoSmithKline, and news from panel discussions on orphan drugs, venture philanthropy and Russia.

You may also be interested in...



Top Changes At Bayer And Novartis As Vasella Goes, Reinhardt Returns

It’s all change at two of Europe’s largest pharmaceutical concerns as leading light Daniel Vasella retires at Novartis and Bayer Healthcare’s chairman Jorg Reinhardt moves across to replace him as non-executive chairman.

GSK Will Be A Limited Partner In Sanderling Ventures’ New Fund

The pharma pledges $50 million to the California firm’s new seventh round, which it anticipates closing more than eight years after its sixth. For GSK, it’s the latest tie-up with a VC firm as part of a regional investment strategy.

Cancer Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

PS075564

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel